Individuals with HIV often have a higher risk of age-related morbidity, despite successful antiretroviral therapy. However, less is known about the risk of accelerated cognitive decline or aging-related...
Two-drug regimens for ART are of interest, in order to minimize drug exposure and toxicity. The efficacy, safety, and tolerability of dolutegravir and rilpivirine suggest that they may be good candidates...
Previous evidence has shown that human immunodeficiency virus and antiretroviral therapy are associated with metabolic disturbances. However, less information currently exists regarding the effect of body...
In a recent study, researchers evaluated the safety and immunogenicity of a new double recombinant vaccine for the prevention of human immunodeficiency virus infection.
After the recent approval of Juluca, the first two-drug regimen for HIV, drugmakers are focusing on making new HIV treatments more accessible and convenient.
After 2 clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved the first complete HIV treatment regimen containing only 2 drugs.
Previous studies have shown that age-related conditions have become increasingly common in patients with HIV, indicating a need to evaluate the potential association of this prevalence with clinical care...
In a recent study, researchers evaluated changes in viral suppression status from 2013 to 2014 in patients with HIV, as well as factors associated with these changes.
Using the CDC’s National HIV Behavioral Surveillance, researchers examined coverage rates and disparities in linkage to care and antiretroviral treatment among HIV-positive men who have sex with men.
Although marijuana and alcohol use have been shown to negatively impact cognition, the effects of current and lifetime substance and alcohol use on cognitive dysfunction among individuals with HIV are not...
